Home/Filings/4/0000899243-20-034284
4//SEC Filing

Sinha Uma 4

Accession 0000899243-20-034284

CIK 0001743881other

Filed

Dec 16, 7:00 PM ET

Accepted

Dec 17, 4:05 PM ET

Size

11.4 KB

Accession

0000899243-20-034284

Insider Transaction Report

Form 4
Period: 2020-12-15
Sinha Uma
Chief Scientific Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2020-12-15+8,9128,912 total
    Exercise: $3.07Exp: 2030-04-01Common Stock (8,912 underlying)
  • Award

    Stock Option (Right to Buy)

    2020-12-15+5,7175,717 total
    Exercise: $42.80Exp: 2030-09-29Common Stock (5,717 underlying)
  • Award

    Stock Option (Right to Buy)

    2020-12-15+10,83210,832 total
    Exercise: $3.07Exp: 2030-07-20Common Stock (10,832 underlying)
Footnotes (4)
  • [F1]The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in a privately-held subsidiary of the Issuer. The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio.
  • [F2]3,342 shares subject to the stock option were vested as of the date of acquisition, 186 shares shall vest on January 1, 2021, and 5,384 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date.
  • [F3]4,062 shares subject to the stock option were vested as of the date of acquisition, 226 shares shall vest on January 1, 2021, and 6,544 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date.
  • [F4]2,144 shares subject to the stock option were vested as of the date of acquisition, 119 shares shall vest on January 1, 2021, and 3,454 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date.

Issuer

BridgeBio Pharma, Inc.

CIK 0001743881

Entity typeother

Related Parties

1
  • filerCIK 0001742587

Filing Metadata

Form type
4
Filed
Dec 16, 7:00 PM ET
Accepted
Dec 17, 4:05 PM ET
Size
11.4 KB